2-Decarboxy-2-hydroxymethyl-6-keto-PGE.sub.1 compounds

Abstract
Prostaglandin E (PGE)-type derivatives and analogs having a 6-keto feature are disclosed, including processes for preparing them and the appropriate intermediates, said derivatives having pharmacological activity.
Description

DESCRIPTION
BACKGROUND OF THE INVENTION
The present invention relates to novel 2-decarboxy-2-hydroxymethyl-6-keto-PGE.sub.1 compounds which are useful agents for the induction of prostacyclin-like pharmacological effects. Accordingly, these compounds are useful for pharmacological purposes for which prostacyclin and related substances are employed. The essential material constituting disclosure of the preparation and use of these novel compounds is incorporated here by reference from Ser. No. 829,679, filed Sept. 2, 1977.
SUMMARY OF THE INVENTION
The present invention particularly provides a compound of the formula ##STR1## wherein W.sub.1 is .alpha.-OH:.beta.-H, .beta.-H:.beta.-OH, .alpha.-H:.beta.-H, methylene, or .alpha.-CH.sub.2 OH:.beta.-H;
wherein Q is oxo, .alpha.-H:.beta.-H, .alpha.-R.sub.8 :.beta.-OH, or .alpha.-OH:.beta.-R.sub.8, wherein R.sub.8 is hydrogen or alkyl of one to 4 carbon atoms, inclusive;
wherein R.sub.4 is
(1) --C(R.sub.5)(R.sub.6)--C.sub.g H.sub.2g --CH.sub.3
(2) --C(R.sub.5)(R.sub.6)--Z--(Ph) or
(3) cis-CH.sub.2 -CH.dbd.CH-CH.sub.2 CH.sub.3,
wherein C.sub.g H.sub.2g is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between --CR.sub.5 R.sub.6 -- and terminal methyl, wherein R.sub.5 and R.sub.6 are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R.sub.5 and R.sub.6 is fluoro only when the other is hydrogen or fluoro and the further proviso that neither R.sub.5 nor R.sub.6 is fluoro when Z is oxa (--O--); wherein Z represents an oxa atom (--O--) or C.sub.jH2j is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between CR.sub.5 R.sub.6 -- and the (Ph); wherein (Ph) is phenyl or phenyl substituted by (T)s,
wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR.sub.7, wherein R.sub.7 is alkyl of one to 4 carbon atoms, inclusive,
wherein s is zero, one, 2 or 3, with the proviso that not more than two T's are other than alkyl and when s is 2 or 3 the T's are either the same or different;
wherein D is
(1) --(CH.sub.2).sub.d --C(R.sub.2).sub.2 --
(2) --CH.sub.2 --O--CH.sub.2 --Y-- or
(3) --CH.sub.2 --CH.dbd.CH--
wherein d is zero to 5, R.sub.2 is hydrogen, methyl, or fluoro, being the same or different with the proviso that one R.sub.2 is not methyl when the other is fluoro, and Y is a valence bond, --CH.sub.2 -- or --(CH.sub.2).sub.2 --, and
wherein X is
(1) trans--CH.dbd.CH--
(2) cis--CH.dbd.CH--
(3) --C.tbd.C--
(4) --CH.sub.2 CH.sub.2 --.
With regard to the divalent substituents described above, e.g., Q and W.sub.1, these divalent radicals are defined as .alpha.-R.sub.i :.beta.-R.sub.j, where Ri represents a substituent of the divalent moiety of the alpha configuration with respect to the cyclopentane ring and R.sub.j represents a substituent to the divalent moiety of the beta configuration with respect to the cyclopentane ring. Accordingly, when Q is defined as .alpha.-OH:.beta.-R.sub.8, the hydroxy of the Q moiety is in the alpha configuration, i.e. as in prostacyclin, and the R.sub.8 substituent is in the beta configuration. Not all carbon atoms to which such divalent moieties are attached represent asymmetric centers. For example, when both valence bonds are to hydrogen (e.g., W.sub.1 or Q is .alpha.-H:.beta.-H), then no asymmetric center is present.





DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention particularly relates to the following chemical compounds:
2-decarboxy-2-hydroxymethyl-6,15-diketo-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-16,16-dimethyl-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-16-phenoxy-17,18,19,20-tetranor-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-16-phenyl-17,18,19,20-tetranor-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-17-phenyl-18,19,20-trinor-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-15(S)-15-methyl-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-(15R)-15-methyl-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-6-keto-13,14-didehydro-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-6-keto-13,14-didehydro-(15R)-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-6-keto-13,14-dihydro-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-2,2-difluoro-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-2,2-difluoro-16,16-dimethyl-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-2,2-difluoro-16-phenoxy-17,18,19,20-tetranor-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-2,2-difluoro-(15S)-15-methyl-6-keto-PGE.sub.1 ;
2-decarboxy-2-hydroxymethyl-2,2-difluoro-13,14-didehydro-6-keto-PGE.sub.1 ; and
2-decarboxy-2-hydroxymethyl-2,2-difluor-13,14-dihydro-6-keto-PGE.sub.1.
Claims
  • 1. A compound of the formula ##STR2## wherein W.sub.1 is .alpha.-OH:.beta.-H, .alpha.-H.beta.-OH, .alpha.-H:.beta.-H, methylene, or .alpha.-CH.sub.2 OH:.beta.-H;
  • wherein Q is oxo, .alpha.-H:.beta.-H, .alpha.-R.sub.8 :.beta..alpha.-OH, or .alpha.-OH:.beta.-R.sub.8, wherein R.sub.8 is hydrogen or alkyl of one to 4 carbon atoms, inclusive;
  • wherein R.sub.4 is
  • (1) --C(R.sub.5)(R.sub.6)--C.sub.g H.sub.2g --CH.sub.3
  • (2) --C(R.sub.5)(R.sub.6)--Z--(Ph) or
  • (3) cis--CH.sub.2 --CH.dbd.CH--CH.sub.2 CH.sub.3,
  • wherein C.sub.g H.sub.2g is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between --CR.sub.5 R.sub.6 -- and terminal methyl, wherein R.sub.5 and R.sub.6 are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R.sub.5 and R.sub.6 is fluoro only when the other is hydrogen or fluoro and the further proviso that neither R.sub.5 nor R.sub.6 is fluoro when Z is oxa (--O--); wherein Z represents an oxa atom (--O--) or C.sub.j H.sub.2j is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between CR.sub.5 R.sub.6 -- and the (Ph); wherein (Ph) is phenyl or phenyl substituted by (T)s,
  • wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR.sub.7 -- wherein R.sub.7 is alkyl of one to 4 carbon atoms, inclusive, and
  • wherein s is zero, one, 2 or 3, with the proviso that not more than two T's are other than alkyl and when s is 2 or 3 the T's are either the same or different;
  • wherein D is
  • (1) --(CH.sub.2).sub.d --C(R.sub.2).sub.2--
  • (2) --CH.sub.2 --O--CH.sub.2 --Y-- or
  • (3) --CH.sub.2 CH.dbd.CH--
  • wherein d is zero to 5, R.sub.2 is hydrogen, methyl, or fluoro, being the same or different with the proviso that one R.sub.2 is not methyl when the other is fluoro, and Y is a valence bond, --CH.sub.2 -- or --(CH.sub.2).sub.2 --, and
  • wherein X is
  • (1) trans--CH.dbd.CH--
  • (2) cis--CH.dbd.CH--
  • (3) --C.tbd.C--
  • (4) --CH.sub.2 CH.sub.2 --.
  • 2. A compound according to claim 1 wherein W.sub.1 is .alpha.-OH:.beta.-H.
  • 3. A compound according to claim 2 wherein D is --(CH.sub.2).sub.d --C(R.sub.2).sub.2 -- wherein d and R.sub.2 are as defined in claim 1.
  • 4. A compound according to claim 3 wherein D is --(CH.sub.2).sub.3 --.
  • 5. A compound according to claim 4 wherein X is trans-CH.dbd.CH--.
  • 6. A compound according to claim 5 wherein Q is oxo.
  • 7. 2-Decarboxy-2-hydroxymethyl-15-deoxy-6,15-diketo-PGE.sub.1, a compound according to claim 6.
  • 8. A compound according to claim 5 wherein Q is .alpha.-OH:.beta.-R.sub.8, wherein R.sub.8 is hydrogen, methyl or ethyl.
  • 9. A compound according to claim 8 wherein R.sub.8 is hydrogen.
  • 10. 2-Decarboxy-2-hydroxymethyl-6-Keto-PGE.sub.1, a compound according to claim 9.
  • 11. 2-Decarboxy-2-hydroxymethyl-16,16-dimethyl-6-keto-PGE.sub.1, a compound according to claim 9.
  • 12. 2-Decarboxy-2-hydroxymethyl-16-phenoxy-17,18,19,20-tetranor-6-keto-PGE.sub.1, a compound according to claim 9.
  • 13. 2-Decarboxy-2-hydroxymethyl-16-phenyl-17,18,19,20-tetranor-6-keto-PGE.sub.1, a compound according to claim 9.
  • 14. 2-Decarboxy-2-hydroxymethyl-17-phenyl-18,19,20-trinor-6-keto-PGE.sub.1, a compound according to claim 9.
  • 15. A compound according to claim 8 wherein R.sub.8 is methyl.
  • 16. 2-Decarboxy-2-hydroxymethyl-15(S)-15-methyl-6-keto-PGE.sub.1, a compound according to claim 15.
  • 17. A compound according to claim 5 wherein Q is .alpha.-R.sub.8 :.beta.-OH, wherein R.sub.8 is hydrogen, methyl or ethyl.
  • 18. 2-Decarboxy-2-hydroxymethyl-(15R)-15-methyl-6-keto-PGE.sub.1, a compound according to claim 17.
  • 19. A compound according to claim 4 wherein X is --C.tbd.C--.
  • 20. A compound according to claim 19 wherein Q is .alpha.-OH:.beta.-R.sub.8, wherein R.sub.8 is hydrogen, methyl or ethyl.
  • 21. 2-Decarboxy-2-hydroxymethyl-6-keto-13,14-didehydro-PGE.sub.1, a compound according to claim 20.
  • 22. A compound according to claim 19 wherein Q is .alpha.-R.sub.8 :.beta.-OH wherein R.sub.8 is hydrogen, methyl or ethyl.
  • 23. 2-Decarboxy-2-hydroxymethyl-6-keto-13,14-didehydro-(15R)-PGE.sub.1, a compound according to claim 22.
  • 24. A compound according to claim 4 wherein X is --CH.sub.2 CH.sub.2 --.
  • 25. 2-Decarboxy-2-hydroxymethyl-6-keto-13,14-dihydro-PGE.sub.1, a compound according to claim 24.
  • 26. A compound according to claim 3 wherein D is --(CH.sub.2).sub.2 --CF.sub.2 --.
  • 27. A compound according to claim 26 wherein X is trans--CH.dbd.CH--.
  • 28. A compound according to claim 27 wherein Q is .alpha.-OH:.beta.-H.
  • 29. 2-Decarboxy-2-hydroxymethyl-2,2-difluoro-6-keto-PGE.sub.1, a compound according to claim 28.
  • 30. 2-Decarboxy-2-hydroxymethyl-2,2-difluoro-16,16-dimethyl 6-keto-PGE.sub.1, a compound according to claim 28.
  • 31. 2-Dicarboxy-2-hydroxymethyl-2,2-difluoro-16-phenoxy-17,18,19,20-tetranor-6-keto-PGE.sub.1, a compound according to claim 28.
  • 32. A compound according to claim 27 wherein Q is .alpha.-OH:.beta.-CH.sub.3.
  • 33. 2-Decarboxy-2-hydroxymethyl-2,2-difluoro-(15S)-15-methyl-6-keto-PGE.sub.1, a compound according to claim 32.
  • 34. A compound according to claim 26 wherein X is --C.tbd.C--.
  • 35. 2-Decarboxy-2-hydroxymethyl-2,2-difluoro-13,14-didehydro-6-keto-PGE.sub.1, a compound according to claim 34.
  • 36. A compound according to claim 26 wherein X is --CH.sub.2 CH.sub.2 --.
  • 37. 2-Decarboxy2-hydroxymethyl-2,2-difluoro-13,14-dihydro-6-keto-PGE.sub.1, a compound according to claim 36.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of co-pending application Ser. No. 829,679, filed Sept. 2, 1977, now pending issuance; which is a continuation-in-part of Ser. No. 755,675, filed Dec. 30, 1976, now abandoned.

US Referenced Citations (1)
Number Name Date Kind
4131738 Smith Dec 1978
Non-Patent Literature Citations (1)
Entry
Tanaka et al., "Tett. Letters", p. 1535, (1975).
Divisions (1)
Number Date Country
Parent 829679 Sep 1977
Continuation in Parts (1)
Number Date Country
Parent 755675 Dec 1976